ARSB

Across TCGA pan-cancer cohorts, ARSB Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated ARSB data layer compared with 22 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in uveal melanoma (UVM), where higher ARSB Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated ARSB expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

UVM, LGG, and PRAD are the cancer types where ARSB Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UVM	DFS	Median	All	0.079	0.746	<.001	18	view →
LGG	DFS	Median	All	0.185	0.832	<.001	12	view →
PRAD	OS	Median	All	0.080	0.990	<.001	12	view →
UCEC	DFS	Median	All	0.953	0.622	.035	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

ARSB–UVM (DFS)

Open the UVM breakdown →